Given the rapid emergence of resistance to monotherapy in cancer, we investigated whether combination BRD4i with WEE1 or ATR inhibition would be a strategy to exploit ARID1A loss by targeting two critical pathways critical for survival. The gene discussed is ATR; the disease is cancer.